A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Cetuximab
Related studies linked through entity extraction aliases.
Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer
- Status
- COMPLETED
- Phase
- NA
Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study
- Status
- TERMINATED
- Phase
- PHASE2
Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET).
- Status
- UNKNOWN
- Phase
- PHASE2
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)
- Status
- COMPLETED
- Phase
- PHASE2
Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)
- Status
- COMPLETED
- Phase
- PHASE1
Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
- Status
- COMPLETED
- Phase
- PHASE1
Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
- Status
- COMPLETED
- Phase
- PHASE3
Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection
- Status
- COMPLETED
- Phase
- NA
Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck
- Status
- TERMINATED
- Phase
- PHASE3
Temsirolimus and Cetuximab in Patients With Advanced or Metastatic Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy
- Status
- TERMINATED
- Phase
- PHASE1